Similarly, in a recent preclinical study, mice immunized intraperitoneally (i.p.)with three neoantigen SLPs together with adjuvant showed potent therapeutical CD8+ T cell responses against MC-38 tumor with complete inhibition of tumor growth in 11 of 15 vaccinated mice (19). The gene discussed is CD8A; the disease is neoplasm.